Gastrointestinal complications of schistosomiasis

Current Gastroenterology Reports

Volumn 3, Issue 4, 2001, Pages 293-303

  Schafer, Theodore W ^a   Hale, Braden R ^b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b NONE

Author keywords

Gastric Varix; Praziquantel; Schistosomiasis; Transjugular Intrahepatic Portosystemic Shunt; Variceal Bleeding

Indexed keywords

ARTICLE; HUMAN; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; STOMACH DISEASE;

HUMANS; SCHISTOSOMIASIS; SCHISTOSOMIASIS MANSONI; STOMACH DISEASES;

EID: 0001394148     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-001-0052-1     Document Type: Article

References (82)

1. Ruffer MA: Note on the presence of Bilharzia haematobium in Egyptian mummies of the 20th dynasty (1250-1000 BC). BJM 1910, 1:16.
2. Colley DG: Ancient Egypt and today: enough scourges to go around. Emerging Infect Dis 1996, 2:362–363.
3. Kiernan F: The blood fluke that saved Formosa. Harper’s, April 1959:45-47.
4. Farley J: Bilharzia: A History of Imperial Tropical Medicine. New York: Cambridge University Press; 1991.
5. Fulford AJC, Butterworth AE, Sturrock RF, Ouma JH: On the use of age-intensity data to detect immunity to parasitic infections with special reference to Schistosoma mansoni in Kenya. Parasitology 1992, 105:219–227.
6. Butterworth AE, Dunne DW, Fulford AJC, et al.: Immunity and morbidity in Schistosoma mansoni infection: quantitative aspects. Am J Trop Med Hyg 1996, 55:109–115.
7. Chitsulo L, Engels D, Montresor A, Savioli L: The global status of schistosomiasis and its control. Acta Tropica 2000, 77:41–51.
8. Geboes K, el-Dosoky I, el-Wahab A, Abou Almagd K: The immunopathology of Schistosoma mansoni granulomas in human colonic schistosomiasis. Virchows Arch A Pathol Anat Histopathol 1990, 416:527–534.
9. Fallon PG: Immunopathology of schistosomiasis: a cautionary tale of mice and men. Immunol Today 2000, 21:29–35.
10. Mathew RC, Boros DL: Anti-L3T4 antibody treatment suppresses granuloma formation and abrogates antigen induced interleukin-2 production in Schistosoma mansoni infection. Infect Immun 1986, 54:820–826.
11. Staedecker M: The development of granulomas in schistosomiasis: genetic backgrounds, regulatory pathways, and specific egg antigen responses that influence the magnitude of disease. Microb Infect 1999, 1:505–510. This concise article summarizes important new developments in the understanding of schistosome-induced granuloma formation.
12. Omer FM, Kurtzhals JA, Riley EM: Maintaining the Immunological balance in parasitic infections: a role for TGF-b? Parasitol Today 2000, 16:18–23.
13. Dessein AJ, Marquet S, Henri S, et al.: Infection and disease in human schistosomiasis mansoni are under distinct major gene control. Microb Infect 1999, 1:561–567. This paper summarizes recent important findings suggesting that burden of disease in schistosomiasis may relate to inheritance of genetic region 5q31-33. This region may play a vital role in cytokine regulation and cellular immunity. The findings have significant implications for vaccine development.
14. Colley DG, Garcia AA, Lambertucci JR, et al.: Immune responses during human schistosomiasis. XII. Differential responses in patients with hepatosplenic disease. Am J Trop Med Hyg 1986, 35:793–802.
15. Dunne DW, Butterworth AE, Fulford AJC, et al.: Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol 1992, 22:1483–1494.
16. Garcia EG, Mitchell GF, Beall JM, Tiu WU: Schistosoma japonicum: the modulation of lung granuloma and inhibition of egg maturation in mice by human sera. Asian Pac J Allergy Immunol 1985, 3:156–160.
17. Wu CH, Giambrone M, Howard DJ, et al.: The nature of collagen in hepatic fibrosis in murine schistosomiasis. Hepatology 1982, 2:366–371.
18. Souza MRDA, Toledo CFD, Borges DR: Thrombocytopenia as a predictor of portal hypertension in schistosomiasis. Dig Dis Sci 2000, 45:1964–1970.
19. Symmers WC: Note on a new form of liver cirrhosis due to the presence of the ova of Bilharzia haematobia. J Pathol Bacteriol 1904, 9:237–239.
20. Cairo Working Group: The use of diagnostic ultrasound in schistosomiasis: attempts at standardization of methodology. Acta Tropica 1992, 51:45–64.
21. Thomas AK, Dittrich M, Kardorff R, et al.: Evaluation of ultrasonographic staging systems for the assessment of Schistosoma mansoni induced hepatic involvement. Acta Tropica 1997, 68:347–356. The authors demonstrate the inherent difficulty in getting reliable interobserver accuracy with ultrasound staging systems. Importantly, they propose modifications to improve the utility of ultrasound in evaluating hepatic schistosomiasis. Early lesions remain difficult to evaluate.
22. Pereira LMMB, Domingues ALC, Spinelli V, McFarlane IG: Ultrasonography of the liver and spleen in Brazilian patients with hepatosplenic schistosomiasis and cirrhosis. Am J Trop Med Hyg 1998, 92:639–642.
23. Stone PJ: Potential use of collagen and elastin degradation markers for monitoring liver fibrosis in schistosomiasis. Acta Tropica 2000, 77:97–99.
24. Bica I, Hamer DH, Stadecker MJ: Hepatic schistosomiasis. Infect Dis Clin North Am 2000, 14:583–604.
25. Denie C, Vachiery F, Elman A, et al.: Systemic and splanchnic hemodynamic changes in patients with hepatic schistosomiasis. Liver 1996, 16:309–312.
26. Strickland GT: Gastrointestinal manifestations of schistosomiasis. Gut 1994, 35:1334–1337.
27. Kiire CF: Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis. BMJ 1989, 298:1363–1365.
28. Pagliaro L, D’Amico G, Sorensen TIA, et al.: Prevention of first bleeding in cirrhosis: a meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med 1992, 117:59–70.
29. da SilviaRohrMR, Siqueria ES, Brant CQ, et al.: Prospective study of bacteremia rate after elastic band ligation and sclerotherapy of esophageal varices in patients with hepatosplenic schistosomiasis. Gastrointest Endosc 1997, 46:321–323.
30. Al Karawi MA, El-Sheikh Mohamed AR, Ahmed AMM, Shariq S, Yasawy MI: Longterm outcome of endoscopic sclerotherapy of variceal bleeding: comparitive study between schistosomiasis and others. Hepato-Gastroenterology 1996, 43:287–292.
31. Contractor QQ, Contractor TQ, Kher YR. Sclerotherapy in bleeding gastric varices of hepatic schistosomiasis. Jf Clin Gastroenterol 1996, 23:97–100.
32. Mostafa I, Omar MM, Nouh A: Endoscopic control of gastric variceal bleeding with butyl cyanoacrylate in patients with schistosomiasis. J Egypt Soc Parasitol 1997, 27:405–410. This method is promising for the management of variceal bleeding in schistosomiasis. The 7.5% overall mortality rate (including one treatment-related death) is an impressive result. The results of this small study need to be independently verified.
33. Hassab MA: Non shunt operation in portal hypertension without cirrhosis. Surg Gynecol Obstet 1970, 131:648–654.
34. De JesusLopes FilhoG, Haddad CM: Late clinical, biochemical endoscopic and electroencephalographic evaluation of patients with schistosomal portal hypertension treated with distal splenorenal shunt. Int J Surg 1998, 83:42–47.
35. Hassab MA: Gastro-esophageal decongestion and splenectomy GEDS (Hassab) in the management of bleeding varices: review of the literature. Intl Surg 1998, 83:38–41.
36. Elliott DE. Schistosomiasis: pathophysiology, diagnosis and treatment. Gastroenterol Clin North Am 1996, 25:599–625.
37. LaBerge JM, Somberg KA, Lake JR, et al.: Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology 1995, 108:1143–1151.
38. Grace ND: Practice guidelines: diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol 1997, 92:1081–1091. This paper presents the current state of the art for the management of variceal bleeding. Knowledge of this material is crucial for any practitioner who manages this most lethal complication of schistosomiasis. As discussed in the text, these guidelines are applicable to patients with schistosomal induced portal hypertensive bleeding.
39. Abdel-Wahab MF, Zakaria S, Kamel M, et al.: High seroprevalence of hepatitis C among risk groups in Egypt. Am J Trop Med Hyg 1994, 51:563–567.
40. Darwish MA, Faris R, Clemens JD, et al.: High seroprevalence of hepatitis A, B, C, and E viruses in residents in an Egyptian village in the Nile delta: a pilot study. Am J Trop Med Hyg 1996, 54:554–558.
41. Madwar MA, Tahawy ME, Strickland GT: The relationship between uncomplicated schistosomiasis and hepatitis B infection. Trans R Soc Trop Med Hyg 1989, 83:233–236.
42. Attia MA: Prevalence of hepatitis B and C in Egypt and Africa. Antiviral Ther 1998, 3(suppl 3):1–9.
43. Frank C, Mohamed MK, Strickland GT, et al.: The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355:887–891. This very well-done cohort study presents the most detailed evidence of the relationship between antischistosomal therapy and the spread of hepatitis C.
44. Souto FJ, Fontes CJ, Martelli CM, et al.: Hepatitis C virus prevalence among an immigrant community to the southern Amazon, Brazil. Mem Inst Oswaldo Cruz 1999, 94:719–723.
45. Badawi A, Michael MS: Risk factors for hepatocellular carcinoma in Egypt: the role of hepatitis-B viral infection and schistosomiasis. Anticancer Res 1999, 19:4563–4568. Hepatocellular carcinoma is a major health problem in Egypt. This evaluation demonstrates the complex interplay of numerous risk factors for the disease. The importance of viral hepatitis and schistosomiasis is noted.
46. Kamal SA, Madwar MA, Peters T, et al.: Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000, 32:172–174. This small study illustrates the problems encountered in treating patients coinfected with HCV and schistosomiasis. Larger studies and studies of combination therapy need to be done. The timing of antischistosomal therapy relative to anti-HCV therapy also remains to be addressed.
47. Maizels RM, Bundy DA, Selkirk ME, et al.: Immunological modulation and evasion by helminth parasites in human populations. Nature 1993, 365:797–805.
48. Rocha MO, Pedroso ER, Lambertucci JR, et al.: Gastro-intestinal manifestations of the initial phase of schistosomiasis mansoni. Ann Trop Med Parasitol 1995, 89:271–278.
49. Smith JH, Said M, Kelada AS: Studies on schistosomal rectal and colonic polyposis. Am J Trop Med Hyg 1977, 26:80–84.
50. Elmasalme FN, Raheem MA, Badawy A, et al.: Rectosigmoid bilharzioma causing intestinal obstruction. J Pediatr Surg 1997, 32:631–633.
51. Zimbalist E, Gettenberg G, Brejt H: Ileocolonic schistosomiasis presenting as lymphoma. Am J Gastroenterol 1987, 82:476–478.
52. Prosser JM, Kasznica J, Gottlieb LS, Wade G: Bilharzial pseudotumors: dramatic manifestation of schistosomiasis: report of a case. Human Pathol 1994, 25:98–101.
53. Dimmette RM, Sproat AF: Rectosigmoid polyps in schistosomiasis. I. General clinical and pathologic considerations. Am J Trop Med Hyg 1955, 4:1057–1067.
54. Mohamed AR, al Karawi M, Yasawy MI: Schistosomal colonic disease. Gut 1990, 31:439–442.
55. Nebel OT, El Masry NA, Castell DO, et al.: Schistosomal disease of the colon: a reversible form of polyposis. Gastroenterology 1974, 64:939–943.
56. Hussein AM, Medany S, Abouel MagdAM, et al.: Multiple endoscopic polypectomies for schistosomal polyposis of the colon. Lancet 1983, 1:673–674.
57. Wright SG, Renton P, Swarbrick ET: Stricture of the descending colon due to schistosomiasis. Postgrad Med J 1976, 52:601–604.
58. Contractor QQ, Benson L, Schulz TB, et al.: Duodenal involvement in Schistosoma mansoni infection. Gut 1988, 29:1011–1012.
59. Kunin J, Bejar J, Eldar S: Schistosomiasis as a cause of rectovaginal fistula: a brief case report. Isr J Med Sci 1996, 32:1109–1111.
60. Atik FA, Lopes Filho GJ, Linhares MdM, et al.: Large intestine obstruction complicated with perforation: a rare manifestation of Schistosoma mansoni infection. Rev Paul Med 1998, 116:1781–1783.
61. Golakai VK, Makunike R: Perforation of terminal ileum and appendix in typhoid enteritis: a report of two cases. East Afr Med J 1997, 74:796–799.
62. Wu TS, Chen TC, Chen RJ, et al.: Schistosoma japonicum infection presenting with colon perforation: case report. Chang Keng I Hsueh 1999, 22:676–681.
63. Abul-Khair MH: Bilhariziasis and prolapse of the rectum. Br J Surg 1976, 63:891–892.
64. Jones HJS, Ibrahim AEK, Deroda J: Schistosomiasis of the appendix in the UK. Br J Clin Pract 1997, 51:183.
65. Katz N, Chaves A, Pellegrino A: A simple device for quantitative stool thick smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 1972, 14:397–400.
66. Engels D, Sinzinkayo E, Gryseels B: Day-to-day egg count fluctuation in Schistosoma mansoni infection and its operational implications. Am J Trop Med Hyg 1996, 54:319.
67. Olds GR, Olveda R, Wu G, et al.: Immunity and morbidity in schistosomiasis japonicum infection. Am J Trop Med Hyg 1996, 55:121–126.
68. Abdel-Hafez MA, Bolbol AH: Fibre-optic sigmoidoscopy compared with the Kato technique in diagnosis and evaluation of the intensity of Schistosoma mansoni infection. Trans R Soc Trop Med Hyg 1992, 86:641.
69. Tsang VCW, Wilkins PP: Immunodiagnosis of schistosomiasis. Immunol Invest 1997, 26:175–188.
70. Van Lieshout L,Polderman AM,DeedlerAM: Immunodiagnosis by determination of the circulating antigens CAA and CCA, in particular in individuals with recent or light infections. Acta Tropica 2000, 77:69–80. The authors present data summarizing the utility of a new serum-based test for schistosomiasis. The data also support use of this method for verifying eradication of disease following treatment. The potential advantage of serum testing over stool testing is evident, although the Katz method remains the gold standard for the diagnosis of schistosomiasis. Further evaluation of CAA and CCA may result in this approach becoming the diagnostic method of choice for schistosomiasis.
71. Nibbeling HAM, vanLieshoutL, Deedler AM: Levels of circulating soluble egg antigen in urine of individuals infected with Schistosoma mansoni before and after treatment with praziquantel. Trans R Soc Trop Med Hyg 1998, 92:675–677.
72. Cioli D, Pica-Mattoccia L, Archer S: Antischistosomal drugs: past present and future. Pharmacol Ther 1995, 68:35–85.
73. Garcia Goyoco C, Nazario-Lopez H, Ruiz Tiben E, et al.: The efficacy of oxamniquine in acute schistosomiasis. Bol Asoc Med P R 1997, 4:63–69.
74. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ: Schistosoma mansoni: reduced efficacy of chemotherapy in infected T-cell deprived mice. Exper Parasitol 1985, 60:348–354.
75. Saconato H, Atallah A: Interventions for treating schistosomiasis mansoni. Cochrane Database Syst Rev 2000, CD000528.
76. McEvoy GK: AFHS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2000.
77. King CH, Muchiri EM, Ouma JH: Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya. Emerging Infect Dis 2000, 6:585–594.
78. Harn DA, Reynolds SR, Chikunguwo S, et al.: Synthetic peptide vaccines for schistosomiasis. Pharm Biotechnol 1995, 6:891–905.
79. Waine GJ, McManus DP: Schistosomiasis vaccine development: the current picture. Bioessays 1997, 19:435–443.
80. Bergquist NR: Schistosomiasis vaccine development: progress and prospects. Mem Inst Oswaldo Cruzd 1998, 93:95–101.
81. Wilson RA, Coulson PS: Strategies for a schistosome vaccine: can we manipulate the immune response effectively? Microbes Infect 1999, 1:535–543.
82. Melvin DM, Brooke MM, Sadun EH: Common Intestinal Helminths of Man. Life Cycle Charts. Atlanta, GA: Centers for Disease Control; 1964.